Increased tumor killing via antibody-mediated cellular cytotoxicity (ADCC), a potent mechanism reliant on the engagement of the Fc receptor CD16 by tumor-reactive antibodies (such as anti-CD20 antibody Rituximab used in B cell malignancies [283]), has also been reported for therapeutic antibodies targeting solid tumors, such as anti-HER2 Trastuzumab and anti-EGFR Cetuximab (clinical response however, was dependent upon additional adoptive transfer of high numbers of ex vivo expanded NK cells) [284,285,286]. This evidence concerns the gene ERBB2 and neoplasm.